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ABSTRACT 
Oral drug delivery system represents one of the main areas of sustained drug delivery system. Floating drug delivery system related 
to oral sustained drug delivery system group, which is capable of floating in the stomach for an exteneded period of time. Ranitidine 
hydrochloride is a histamine H2-receptor antagonist. It is widely prescribed in active duodenal ulcers, gastric ulcers, Zollinger-
Ellison syndrome and GERD. A traditional oral sustained release formulation releases most of the drug at the colon, thus the drug 
should have absorption window either in the colon or throughout the gastrointestinal tract. Ranitidine is absorbed only in the initial 
part of the small intestine and has 50% absolute bioavailability. The aim of the present research is to provide 
a gastroretentive system for sustained release of Ranitidine hydrochloride in the upper part of the gastrointestinal tract in the form of 
floating tablet. Gastroretentive tablets of Ranitidine Hydrochloride were prepared by direct compression technique using polymers 
like Carbopol, Chitosan, Styrene-divinylbenzene and the mixture of Magnesium stearate as a lubricant, Talc as a glidant and Lactose 
as fillers. The results of the present research show that the chitosan and carbopol 940 mixed matrices can be used to modify release 
rates in hydrophilic matrix tablets prepared by direct compression. Incorporation of the highly porous low-density copolymer in the 
matrix tablets provides densities that are lower than the density of the release medium. 17% w/w low density copolymer (based on 
the mass of the tablet) was sufficient to achieve proper in vitro floating behavior for at least 8 h. 
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INTRODUCTION 
Gastro retentive drug delivery systems provide dosage 
forms with a longer residence time in the stomach and 
sustained-release behavior, which can increase 
bioavailability as well as has local action on the 
stomach
1,2
. Increasing gastric residence time can be 
achieved either by floating systems that cause buoyancy 
above gastric fluid
3, 4, 5
 high-density systems that sink to 
the bottom of the stomach
6
, bioadhesive systems that 
adhere to mucosal surfaces
7
, or by expandable systems 
that have limited emptying through the stomach pylorus 
due to swelling or unfolding to a larger size
8
. 
Floating Drug delivery system (FDDS) is an effective 
technology to prolong the gastric retention time in order 
to improve the bioavailability of drug. FDDS are the 
systems that float immediately upon contact with gastric 
fluid present promising approaches for increasing the 
bioavailability of drugs with absorption windows in the 
upper intestine. 
Ranitidine hydrochloride is a histamine H2-receptor 
antagonist. It is widely prescribed in active duodenal 
ulcers, gastric ulcers, Zollinger-Ellison syndrome and 
GERD. A traditional oral sustained release formulation 
releases most of the drug at the colon, thus the drug 
should have absorption window either in the colon or 
throughout the gastrointestinal tract. Ranitidine is 
absorbed only in the initial part of the small intestine 
and has 50% absolute bioavailability.
9
 Moreover, 
colonic metabolism of ranitidine is partly responsible for 
the poor bioavailability of ranitidine from the colon.
10
 
These properties of ranitidine hydrochloride do not 
favor the traditional approach to sustained release 
delivery. Hence, clinically acceptable sustained release 
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dosage forms of ranitidine hydrochloride prepared with 
conventional technology may not be successful. 
Landgraf et al. discovered that certain Cavilink 
polymers exhibit surprising release characteristics. 
When used as carriers for active pharmaceuticals, these 
polymers released their contents over a 24-hour period, 
following near zero-order kinetics. Thus, these materials 
are ideally suited for providing constant blood levels of 
many drugs. It appears the zero order release is 
independent of drug composition or form, and entirely 
dependent upon morphology of particular Cavilink 
polymers. The low density material used in this research 
work is Cavilink
TM 
PSDVB Powder, i.e. Poly (Styrene-
divinylbenzene Copolymer). 
The present investigation concerns the Gastroretentive 
tablets of Ranitidine Hydrochloride were by direct 
compression technique using polymers like Carbopol, 
Carbopol 940, sodium CMC, Styrene-divinylbenzene 
and the mixture of Magnesium stearate as a lubricant, 
Talc as a glidant and Lactose as fillers. 
MATERIALS 
Following materials have used in this study and all other 
materials used were of pharmaceutical grade. 
 
Material supplier 
Ranitidine hydrochloride Mann Pharmaceuticals Pvt. Ltd., Mehsana, India. 
Poly (Styrene Divinyl Benzene) (PSDVB) Polygenetics Inc. (CA, USA) 
Ethanol S.D Fine Chemicals Ltd., Mumbai, India   
Hdrochloric Acid Qualigen Chemicals, India. 
Carbopol 940            S. D. Fine Chemicals Ltd., Mumbai, India. 
Dibasic calcium phosphate  S. D. Fine Chemicals Ltd. 
Lactose     S. D. Fine Chemicals Ltd. 
Talc         S. D. Fine Chemicals Ltd. 
Magnesium stearate                              S. D. Fine Chemicals Ltd. 
  
METHODS 
Estimation of ranitidine hydrochloride 
A solution of ranitidine hydrochloride was prepared in 
0.1 N HCl (pH 1.2) and UV spectrum was taken using 
Shimadzu UV-1601 UV/Vis double beam 
spectrophotometer. The UV maxima of ranitidine 
hydrochloride were found to be 314 nm in 0.1 N HCl. 
Preparation of standard calibration curve of 
ranitidine hydrochloride 
Ranitidine Hydrochloride (10 mg) was dissolved in 0.1 
N HCl and volume was made up to 100 ml in 100 ml 
volumetric flask. This solution (100 mcg/ml) was 
further diluted with 0.1 N HCl to obtain solution of 10 
to 100 mcg/ml. Absorbance of each solution was 
measured at 314 nm using UV/Vis double beam 
spectrophotometer and 0.1 N HCl as reference standard. 
The r2 of the calibration curve was found to be 0.997. 
The results of standard curve preparation are shown in 
the figure 1.  
 
Figure 1: standard curve of ranitidine hydrochloride 
Preparation of floating tablets 
Different tablets formulations were prepared using direct 
compression technique. All the powders were passed 
though 80 mesh sieve. Required quantity of drug, matrix 
polymer and low-density copolymer were mixed 
thoroughly. Talc and magnesium stearate were finally 
added as glident and lubricant respectively. The blend 
was compressed (12 mm diameter, flat punches) using 
multipunch tablet compression machine. Each tablet 
contained 336 mg of ranitidine hydrochloride (336 mg 
equivalent to 300 mg of ranitidine) and other 
pharmaceutical ingredients as listed in table in each 
section.  
Evaluation of powder blend 
6.8
                                                                             
 
Angle of repose 
The angle of repose of the powder blend was determined 
by using funnel method. The accurately weighed 
powder were taken in a funnel. The height of the funnel 
was adjusted in such a way that the tip of the funnel just 
touched the apex of the heap of the powder. The 
diameter of the powder cone was measured and angle of 
repose was calculated by using the equation
3
 
 
Where h and r are the height and radius of the powder 
cone.  
Average values are shown in Table  
Bulk density
  
Both untapped bulk density, ρu (often called loose or 
aerated bulk density) and tapped bulk density, ρb were 
determined. A amount of powder blend was introduced 
in a 10 ml measuring cylinder up to 9 ml volume.Then 
the weight of powder blend was determined by 
y = 0.036x + 0.065 
R² = 0.997 
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substracting the weight of empty measuring cylinder 
from final weight of measuring cylinder. The cylinder 
was allowed to fall onto a hard surface from a height of 
2.5 cm at 2 sec intervals. The tapping was continued till 
no volume change was noted. ρu and ρb were determined 
by following formulas; 
3
 
                                                                                
 
Compressibility Index
  
An important measure that can be obtained from bulk 
density determinations is the percent compressibility C, 
which is defined as follows 
3
 
 
Total Porosity  
Total porosity was determined by measuring the volume 
occupied by a selected weight of a powder (Vbulk) and 
the true volume of the powder blend (The space 
occupied by the powder exclusive of spaces greater than 
the intermolecular spaces, V) 
Porosity (%)=Vbulk-V/Vbulk x 100 
Drug Content
 
An accurately weight amount of ranitidine 
hydrochloride powder blend (100 mg) was extracted 
with 0.1 N HCl and the solution was filter through 0.45 
membrane. The absorbance was measured at 314 nm 
after suitable dilution using a UV/Vis double beam 
spectrophotometer. 
Evaluation of tablets 
Weight variation test
 
 
Weigh 20 tablets selected at random and calculate the 
average weight. Not more than two of the individual 
weights deviate from the average weight by more than 
the percentage limits. As per Indian Pharmacopoeia 
specification.J2          
Drug content 
Five tablets were weighed and powdered. The quantity 
equivalent to 500 mg of Ranitidine axetil was weighed 
accurately and taken in 500-ml volumetric flask. 200 
milliliters of 0.1N HCl was added, sonicated for 5 min, 
made up to 500 ml with 0.1 N HCl, and filtered. From 
above solution further dilution was made and the drug 
concentration was determined at 314 nm by using UV 
spectrophotometer. Drug content was calculated by 
using absorbance at wavelength 314 nm. 
3
 
Hardness  
The hardness of tablet was carried out by using Pfizer 
type hardness tester. The hardness of the tablet kg / cm² 
was measured.
4
 
Thickness 
Control of physical dimension of the tablets such as 
sizes and thickness is essential for consumer acceptance 
and to maintain tablet to tablet uniformity. The 
dimensional specifications were measured using verniar 
calipers. Six tablets from each batch were tested and 
average values were calculated. The thickness of the 
tablet is mostly related to the tablet hardness can be uses 
as initial control parameter. 
4
 
In Vitro dissolution studies 
The release rate of drug from floating tablets was 
determined using The United States Pharmacopoeia 
(USP) XXIV dissolution testing apparatus II (paddle 
method). The dissolution test was performed using 900 
ml of 0.1 N HCl, at 37  0.5C and 75 rpm.9 A sample 
(10 ml) of the solution was withdrawn from the 
dissolution apparatus hourly for 8 hours, and the 
samples were replaced with fresh dissolution medium. 
The samples were filtered through a 0.45  membrane 
filter and diluted to a suitable concentration with 0.1N 
HCl. Absorbance of these solutions was measured at 
314 nm using a UV/Vis double beam 
spectrophotometer. Cumulative percentage of drug 
release was calculated using the equation obtained from 
a standard curve.
6
 
In vitro buoyancy studies 
The tablets were placed in 100 ml beaker containing 0.1 
N HCl. The time required for the tablets to rise to the 
surface and float was determined as floating lag time. 
The pictorial results of in vitro buoyancy study of the 
best batch is shown in figure 5 
Swelling index    
The swelling index of tablets was determined n 0.1 N 
HCl (pH 1.2) at room temperature. The swollen weight 
of the tablets was determined at predefined time 
intervals. The swelling index was calculated by the 
following equation: 
Swelling index = 
   –  
  
 
Where, W0 is the initial weight of tablet, and Wt is the 
weight of the tablet at time t. 
RESULTS AND DISCUSSIONS 
The micromeritic properties of the powder blend of the 
best batch formulation were checked, wherein the angle 
of repose was found to be around 28.61
0
, which shows 
good flowing property of the blend. The loose bulk 
density and the tapped bulk density were found to be 
0.117 g/ml and 0.139 g/ml respectively which is good. 
The compressibility index and total porosity was 
observed to be 16.80 % and 16.44 %. The drug content 
was in the range of 99.89 – 100.06 %, which passes the 
official requirement. The drug content in all the batches 
of ranitidine hydrochloride floating tablets was in the 
range of 98.69 to 101.25 %. This ensured the uniformity 
of the drug content in the tablets. Weight variation data 
of the prepared tablets indicated no significant 
difference in the weight of individual tablet from the 
average value. Hardness of the prepared tablets was 
observed within the range of 5.9 ± 0.2 kg/cm
2
. 
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Thickness of all the tablets was found in the range of 
5.25 ± 0.01 mm. 
In an attempt to determine drug: polymer ratio 
formulation batch F1 was prepared. Dissolution of the 
tablets was carried out using 0.1 N HCl at 37  0.5C 
(900 ml using USP apparatus II at 75 rpm.) The drug 
release was measured. The formulated batch was 
evaluated for the in vitro buoyancy test.  
Table 1: Composition of formulation F1 and F2 of 
floating tablets 
Ingredients F1 F2 
Ranitidine hydrochloride 336 336 
Chitosan  150 - 
Carbopol 940 - 200 
Magnesium stearate 5 5 
Talc 10 10 
* All the quantities are in mg. 
Chitosan was selected as matrix forming polymer since 
the polymer has been investigated as a potential 
adjuvant for swellable controlled drug delivery systems. 
Chitosan was taken as matrixing polymer in the 
concentration of 30 % w/w. The dissolution of batch F1 
in the first hour was 93.56 %. It was thus concluded that 
chitosan alone was not a proper choice to produce 
required integrity of the tablet and prolonged drug 
release. Further it was decided to select carbopol 940 as 
the matrix forming polymer. 
11 
Formulation batch F2 was prepared using carbopol 940 
as the matrix forming agent. It is a polymer of acrylic 
acid and forms hydrogel in water or alkaline solution 
due to hydration of the carboxyl groups in its structure. 
For drugs that are primarily released in the acidic region 
of the gastrointestinal tract (GIT), carbopol 940 seemed 
to be most suitable polymer.
11 
Carbopol 940 in the 
concentration of approximately 36 % in the formulated 
tablets led to gradual swelling of the tablet. The drug 
release was in a controlled manner for a period of >12 
hours. The dissolution profile obtained in the first hour 
was very less which was 22.26 %. The reading obtained 
at 8 hours was 74.56 % which was much below our 
requirement.  But at the same time the problem of 
erosion and loss of integrity was over come with the use 
of carbopol 940.
 
 
 
Figure 2: % CPR of Formulation F1 and F2  
Effect of drug: polymer ratio on drug release 
To determine drug: polymer ratio formulation batch F3, 
F4 and F5 were prepared with a blend of chitosan and 
carbopol 940 in different ratios.  
 
Table 2: Composition of formulation F3, F4 and F5 of floating tablets 
Ingredients    F3 F4 F5 
Ranitidine hydrochloride    336 336 336 
Chitosan     100 25 50 
Carbopol 940    100 100 100 
Magnesium stearate    5 5 5 
Talc    10 10 10 
* All the quantities are in mg. 
 
Figure 3: % CPR of Formulation F3, F4, and F5  
Various ratios of chitosan and carbopol 940 (1:1, 1:4, 
1:2) were taken in Formulation in F3, F4 and F5 
respectively. At the same time batch F3 dispersed 
completely in 7 hours and batch F4 and F5 dispersed 
completely in 8 hours. In the batches containing more 
concentration of chitosan (100 mg) compared to 
carbopol 940 (25 mg, 50 mg and 100 mg) there was 
erosion of the tablets because of the chitosan. Then a 
reverse order was followed i.e. with more concentration 
of carbopol 940 (100 mg) as compared to chitosan (25 
mg and 50 mg) as batches F4 and F5. There was no loss 
of integrity of the tablets in this case. Thus, it became 
clear that there was decrease in loss of integrity with the 
increase in concentration of carbopol 940. This was 
directly proportional to the drug release from the 
hydrophilic matrices. The drug release after the first 
hour, from the formulation batches F4 and F5 was 35.58 
%, and 22.35 % respectively. The in vitro drug release 
after 8 hours, from the formulation batches F4 and F5 
was 101.23 %, and 96.66 % respectively.  
Effect of buoyancy by low density copolymer 
(PSDVB) 
To study the effect of buoyancy by low density 
copolymer i.e. PSDVB on in vitro buoyancy and drug 
dissolution profile different formulation batches 
containing 70 and 100 mg PSDVB copolymer i.e. 
approximately 12 % and 17 % were formulated. 
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Table 3: Composition of formulation F6 and F7 of floating tablets 
Ingredients F6 F7 
Ranitidine hydrochloride 336 336 
Chitosan  
Carbopol 940  
50 
100 
50 
100 
Poly (Styrene-divinylbenzene)  70 100 
Magnesium stearate 5 5 
Talc 10 10 
* All the quantities are in mg 
Table 4: Micromeritic properties of powder blend 
Powder 
blend  
Angle of 
Repose (
0
) 
Loose Bulk 
Density (g/ml) 
Tapped Bulk 
Density (g/ml) 
Compressibility 
Index (%) 
Total 
Porosity (%) 
Drug Content 
(%) 
F7 28.61
 
0.117 0.139 16.68 16.44 98.69 – 101.25 
 
Table 5: Various evaluation parameter of tablets 
Tablets Batch Weight variation test (%) Drug content (%) Hardness (kg/cm
2
) Thickness (mm) 
F7 Av. ± 1.58 100 ± 1.25 5.9 ± 0.2 5.25 ± 0.01 
All the values are expressed as mean  SE. 
 
 
Figure 4: % CPR of Formulation F6, and F7 
The effect of PSDVB copolymer on drug release profile 
was checked out on formulations containing 
approximately 12 % and 17 % of the copolymer. The 
results obtained from in vitro dissolution study revealed 
that there is no significant change in drug dissolution 
profile with increase or decrease in PSDVB low density 
copolymer concentration. During the in vitro buoyancy 
test, a significant change was observed in the floating 
lag time of the formulation with increased amount of 
PSDVB. No floating of the tablets was achieved in 
lower concentrations of PSDVB copolymer ie. upto 12 
%. Evaluating all the parameters batch F7 was selected 
as the optimized batch since it had the minimum 
concentration of low density copolymer required to float 
the tablets. 
In vitro Floating Behaviour of batch F7 
The pictorial results of in vitro buoyancy study of the 
best batch is shown in figure 5, which clearly depicts the 
floating lag time, stable and persistent buoyancy and 
swelling characteristic of tablet.  
Swelling index of batch F7 
Tablets composed of polymeric matrices build a gel 
layer around the tablet core when they come in contact 
with water this gel layer governs the drug release. 
Kinetics of swelling is important because the gel barrier 
is formed with water penetration. Swelling is also vital 
factor to ensure floating. To obtain floating, the balance 
between swelling and water acceptance must be 
restored. The swelling index of the best batch after 8 
hours was 1.31 which may be because of high viscosity 
and high water retention property of carbopol 940.
                
                                     At initial time                                                  After 8 hour 
Figure 5: Swelling index of batch F7 
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Kinetic modeling of drug release of batch F7 
The dissolution profile of the best batch was fitted to 
zero-order, first-order, Higuchi and Hixon-Crowell 
models to ascertain the kinetic modeling of drug release. 
The method of Bamba et al was adopted for deciding the 
most appropriate model. To analyze the mechanism of 
drug release from the matrix tablets, the release data 
were fitted to the following equations: 
Zero-order equation:    
m = k0t 
Where m is the % drug unreleased at time t, and k0 is the 
release rate. 
First-order equation:   
m = e
a 
x e
-bt 
Where a is the intercept and b is the slope 
Higuchi’s equation:    
m = 100 – q x sq root of time 
Where q is the Higuchi constant (% per sq root of time)  
Hixon – Crowell equation:   
m = ((100) x (1/3) – k x t) 3 
Where k is Hixon Crowell constant (mass/(time))
1/3
Table 6: Results of model fitting of batch F7
 
                                            Intercept                 Slope                        R
2    
                       F-value 
Zero-order plot 
First-order plot 
Higuchi plot 
Hixon Crowell 
+ 18.518 
+ 4.843 
- 1.511 
+ 5.571
 
+ 0.188 
+ 0.756 
+ 4.655 
+ 0.384 
0.9115 
0.5297 
0.9944 
0.9584 
106.72 
141.17 
6.81 
10.06 
 
CONCLUSION 
In the curreny research work blend of the chitosan – 
carbopol 940 can be used to modify rate of release in 
prepared tablets. Addition of the porous low density 
copolymer in the tablets provides densities that are lower 
than the density of the release medium. Around 16 % 
w/w this low density copolyme was sufficient to obtain 
desired in vitro floating behavior for at least 8 h. 
Extended floating times are achieved due to the air 
entrapped within the low density copolymer particles, 
which is only slowly removed from the system upon 
contact with the release medium. As expected, tablets 
without low density copolymer (e.g., consisting of 50 
mg chitosan, 100 mg carbopol 940 and 336 mg 
ranitidine hydrochloride first sank before floating, 
showing no floating lag times. Adding only 17% w/w 
(based on the mass of the tablet) of the PSDVB 
copolymer reduced the lag times to 10 seconds. The 
other most important thing that can be concluded from 
the study was that the formulation and process variables 
play sole role in the release behavior of the matrices. 
Faster release of the drug from the hydrophilic matrix 
was probably due to faster dissolution of the highly 
water-soluble drug from the core and its diffusion out of 
the matrix forming the pores for entry of solvent 
molecules. So, we can obtain a formulation that has 
desired release profile by adjusting different parameters 
that ultimately effect release behavior of the matrices.  
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